Compare Novo Nordisk A/S (NVO) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs QUALCOMM, Inc. — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while QUALCOMM, Inc. trades at $173.24 (market cap $179.52B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | QCOM | |
|---|---|---|
Market Cap | $220.53B | $179.52B |
Sector | Health | Technology |
52-Week High | $71.70 | $251.10 |
52-Week Low | $35.29 | $124.07 |
Enterprise Value | $239.49B | $184.99B |
Dividend Yield | 3.63% | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Qualcomm (QCOM) trades at $171.78, up 0.64% with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 54.8% gross margins and 22.31% net income margins, though revenue growth remains modest. Recent news highlights Qualcomm's AI and data center expansion efforts while facing smartphone market headwinds and increased competition from Nvidia's PC chip entry.
The stock presents a mixed outlook with attractive valuation (P/E 18.31) and analyst consensus target of $228.22 offering 33% upside potential. However, margin pressures and competitive threats from Nvidia's market expansion create near-term uncertainty. Institutional sentiment leans neutral with 50% hold ratings, suggesting cautious optimism about Qualcomm's diversification strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
